Shares of Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) have been assigned a consensus rating of “Strong Buy” from the seven analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have given a strong buy recommendation to the company.
Separately, Citizens Jmp raised Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, December 9th.
Check Out Our Latest Stock Report on GLX
Bradmer Pharmaceuticals Price Performance
Read More
- Five stocks we like better than Bradmer Pharmaceuticals
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
